![Teva Issues Voluntary Nationwide Recall of One Lot of IDArubicin Hydrochloride Injection USP 5 mg/5 mL Due to the Presence of Particulate Matter | FDA Teva Issues Voluntary Nationwide Recall of One Lot of IDArubicin Hydrochloride Injection USP 5 mg/5 mL Due to the Presence of Particulate Matter | FDA](https://www.fda.gov/files/styles/recall_image_small/public/image-1_53.png?itok=-VZ3-Pnq)
Teva Issues Voluntary Nationwide Recall of One Lot of IDArubicin Hydrochloride Injection USP 5 mg/5 mL Due to the Presence of Particulate Matter | FDA
![Teva Pharmaceuticals found to be responsible for its role in the opioid epidemic in New York State | CNN Teva Pharmaceuticals found to be responsible for its role in the opioid epidemic in New York State | CNN](https://media.cnn.com/api/v1/images/stellar/prod/211230154406-teva-pharmaceuticals-file-2021.jpg?q=h_1332,w_2000,x_0,y_0)
Teva Pharmaceuticals found to be responsible for its role in the opioid epidemic in New York State | CNN
![Omeprazole Generic Drug Box by Teva Closeup Against White Editorial Image - Image of american, generics: 187803275 Omeprazole Generic Drug Box by Teva Closeup Against White Editorial Image - Image of american, generics: 187803275](https://thumbs.dreamstime.com/z/kyiv-ukraine-may-gastroenterology-generic-drug-omeprazole-teva-box-closeup-white-teva-pharmaceuticals-american-israeli-187803275.jpg)
Omeprazole Generic Drug Box by Teva Closeup Against White Editorial Image - Image of american, generics: 187803275
Teva Pharmaceuticals on LinkedIn: #tevapharm #pridemonth #tevapride #beyondstereotypes #celebratingwithpride
![ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business](https://mms.businesswire.com/media/20180914005613/en/678526/5/AJOVY+Image.jpg?download=1)
ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business
![Boston Jury Awards Teva Pharmaceuticals $176.5M for Eli Lilly's Migraine Medication Patent Infringement | Law.com Boston Jury Awards Teva Pharmaceuticals $176.5M for Eli Lilly's Migraine Medication Patent Infringement | Law.com](https://images.law.com/contrib/content/uploads/sites/292/2022/11/Teva-767x633.jpg)